Advaxis Inc. buy stratec
Start price
24.01.18
/
50%
€41.67
Target price
03.12.18
€121.77
Performance (%)
-86.69%
End price
03.12.18
€5.55
Summary
This prediction ended on 03.12.18 with a price of €5.55. The BUY prediction by stratec for Advaxis Inc. performed very badly with a performance of -86.69%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Advaxis Inc. | - | - | - | - |
| iShares Core DAX® | -1,03 % | -9,17 % | -1,56 % | 49,94 % |
| iShares Nasdaq 100 | -1,95 % | -2,62 % | 11,25 % | 77,36 % |
| iShares Nikkei 225® | -0,42 % | -9,42 % | 24,93 % | 51,28 % |
| iShares S&P 500 | -1,20 % | -2,99 % | 7,52 % | 59,46 % |
Comments by stratec for this prediction
In the thread Advaxis Inc. diskutieren
stratec stimmt der Buy-Einschätzung von tamam zu
stratec stimmt am 24.01.2018 der Buy-Einschätzung von tamam mit dem Kursziel 10$ zu.
Überschrift: ADXS has very interesting make-or-break potential, caveat emptor!
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
ADXS reports that 8 of 9 patients were progression-free at the 42 months mark. If researchers could reproduce this in a wider patient population, then addition of the Lm-based immunotherapy might represent a new standard of care.
(Vom Mitglied beendet)